Insights and Analysis
AI-washing – when AI hype becomes a litigation risk
Yu-An Chang (Shanghai IP Agency)
Counsel Intellectual Property
Languages
English, Mandarin, Taiwanese
His practice spans the full spectrum of intellectual property law. He advises clients across industries on complex, technology-driven transactions and high-stakes disputes in China and beyond.
He advises on licensing, technology transfers, joint ventures, and strategic collaborations, as well as commercial arrangements supporting business expansion into new markets and sectors. He also advises on IP aspects of mergers and acquisitions, IPOs, financings, investments, and restructurings, where intellectual property is a key asset.
On the contentious side, he represents global brands in trademark, copyright, and patent enforcement, developing practical strategies that protect IP rights and strengthen market position.
He has supported clients across industries including technology, pharmaceuticals, medical devices, chemicals, energy, education, consumer goods, and retail, where innovation and intellectual property protection are critical to growth.
Advised a multinational pharmaceutical company on acquisition and licensing of a novel clinical-stage bispecific antibody with Chinese partners, enabling multi-jurisdictional development
Advised a multinational conglomerate on structuring IP and technology licensing and transfer arrangements with Chinese partners to manufacture commercial and industrial energy storage systems
Advised a leading international toy company on trademark, copyright and patent protection, enforcement, and licensing strategies in China
Advised a global medical device company in an IP and technology collaboration with a Chinese partner to develop advanced surgical navigation systems
Advised a international conglomerate on IP and technology licensing arrangements with a Chinese partner for production and distribution of high-performance chemicals across Asia Pacific
Advising international companies on IP aspects of technology-driven mergers and acquisitions, restructurings, and investments in China
Advising international brands in China on IP protection, enforcement and portfolio management strategies to safeguard innovation and strengthen market position
Advising multinational pharmaceutical companies on licensing and collaboration arrangements with Chinese biotech firms